CA2861339C - Metalloenzyme inhibitor compounds - Google Patents

Metalloenzyme inhibitor compounds Download PDF

Info

Publication number
CA2861339C
CA2861339C CA2861339A CA2861339A CA2861339C CA 2861339 C CA2861339 C CA 2861339C CA 2861339 A CA2861339 A CA 2861339A CA 2861339 A CA2861339 A CA 2861339A CA 2861339 C CA2861339 C CA 2861339C
Authority
CA
Canada
Prior art keywords
compound
disease
metalloenzyme
mmol
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861339A
Other languages
English (en)
French (fr)
Other versions
CA2861339A1 (en
Inventor
William J. Hoekstra
Robert J. Schotzinger
Stephen W. Rafferty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycovia Pharmaceuticals Inc
Original Assignee
Mycovia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc filed Critical Mycovia Pharmaceuticals Inc
Publication of CA2861339A1 publication Critical patent/CA2861339A1/en
Application granted granted Critical
Publication of CA2861339C publication Critical patent/CA2861339C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2861339A 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds Active CA2861339C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589076P 2012-01-20 2012-01-20
US61/589,076 2012-01-20
PCT/US2013/022313 WO2013109998A1 (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
CA2861339A1 CA2861339A1 (en) 2013-07-25
CA2861339C true CA2861339C (en) 2020-08-25

Family

ID=48799718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861339A Active CA2861339C (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Country Status (14)

Country Link
US (3) US10221160B2 (instruction)
EP (1) EP2804858B1 (instruction)
JP (1) JP6189865B2 (instruction)
KR (1) KR102061137B1 (instruction)
CN (1) CN104136427B (instruction)
AU (2) AU2013209516A1 (instruction)
BR (1) BR112014017751B1 (instruction)
CA (1) CA2861339C (instruction)
DK (1) DK2804858T3 (instruction)
EA (1) EA026209B1 (instruction)
ES (1) ES2774267T3 (instruction)
IN (1) IN2014DN06792A (instruction)
PL (1) PL2804858T3 (instruction)
WO (1) WO2013109998A1 (instruction)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6159318B2 (ja) 2011-06-19 2017-07-05 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
BR112014017751B1 (pt) * 2012-01-20 2021-12-07 Mycovia Pharmaceuticals, Inc Compostos inibidores de metaloenzima, composições compreendendo os ditos compostos e uso dos ditos compostos
JP6509897B2 (ja) 2014-03-19 2019-05-08 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
KR102441242B1 (ko) 2014-03-19 2022-09-07 브이피에스-3, 엘엘씨 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
CA2942982C (en) 2014-03-19 2023-09-19 Viamet Pharmaceuticals, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
WO2015143184A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017507991A (ja) * 2014-03-19 2017-03-23 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
EP3119749A4 (en) * 2014-03-19 2017-12-13 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2015143180A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
KR20160138013A (ko) * 2014-03-19 2016-12-02 비아멧 파마슈티컬즈, 인코포레이티드 항진균 화합물 제조방법
EP3119764B1 (en) * 2014-03-19 2019-04-17 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
PL3271347T3 (pl) 2015-03-19 2022-11-21 Mycovia Pharmaceuticals, Inc. Związki przeciwgrzybicze i sposoby wytwarzania
WO2017049196A1 (en) 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Antifungal compounds and processes for making
AU2016380349B2 (en) * 2015-12-30 2020-10-29 Nqp 1598, Ltd. Metalloenzyme inhibitor compounds
EP3559009B1 (en) 2016-12-22 2021-04-07 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
CN109810049B (zh) * 2018-11-30 2021-01-15 深圳大学 一种含吡啶的化合物及其提取方法
TW202140445A (zh) * 2020-01-17 2021-11-01 大陸商上海森輝醫藥有限公司 四氮唑類化合物的可藥用鹽及其結晶形式、製備方法和用途
IL302082A (en) * 2020-10-16 2023-06-01 Miralogx Llc Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8304282D0 (en) * 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
GB8305377D0 (en) * 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
GB8415889D0 (en) * 1984-06-21 1984-07-25 Ici Plc Antifungal azole compounds
AU4327585A (en) 1984-06-21 1986-01-02 Imperial Chemical Industries Plc Antifungal azole compounds
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
GB9121456D0 (en) * 1991-10-10 1991-11-27 Pfizer Ltd Triazole antifungal agents
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5358939A (en) 1992-06-25 1994-10-25 Rohm And Haas Company Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CA2667054C (en) 2006-10-18 2011-05-10 Bnl Biotech Co., Ltd. Endodontic instrument for root canal filling and heating tip adapted to the same
US8680270B2 (en) 2006-11-21 2014-03-25 Viamet Pharmaceuticals, Inc. Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties
US8221057B2 (en) 2008-06-25 2012-07-17 General Electric Company Method, system and controller for establishing a wheel space temperature alarm in a turbomachine
JP2012501979A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー ある種のさび菌を防除するための殺真菌性化合物組成物の使用
US8987315B2 (en) * 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
RS55010B1 (sr) * 2010-04-24 2016-11-30 Viamet Pharmaceuticals Inc Jedinjenja koja inhibiraju metaloencime
AU2011320565A1 (en) * 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP5828343B2 (ja) * 2010-11-13 2015-12-02 イノクリン ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害化合物
EP2651905B1 (en) * 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20180095108A (ko) * 2011-06-19 2018-08-24 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
JP6159318B2 (ja) * 2011-06-19 2017-07-05 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
PH12013502622A1 (en) * 2011-06-23 2014-02-10 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
AU2012300275A1 (en) * 2011-08-30 2014-03-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP6085613B2 (ja) * 2011-12-11 2017-02-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害薬化合物
BR112014017751B1 (pt) * 2012-01-20 2021-12-07 Mycovia Pharmaceuticals, Inc Compostos inibidores de metaloenzima, composições compreendendo os ditos compostos e uso dos ditos compostos
AU2013209520A1 (en) * 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
JP2016508487A (ja) * 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
CN105431418B (zh) * 2013-06-12 2019-02-05 北卡罗来纳维亚梅特制药公司 金属酶抑制剂化合物
WO2015160664A1 (en) * 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CN106231901A (zh) * 2014-04-15 2016-12-14 美国陶氏益农公司 作为杀真菌剂的金属酶抑制剂化合物
CA3055292A1 (en) * 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
US11247981B2 (en) 2022-02-15
KR102061137B1 (ko) 2019-12-31
ES2774267T3 (es) 2020-07-20
EP2804858A1 (en) 2014-11-26
US10221160B2 (en) 2019-03-05
US10526312B2 (en) 2020-01-07
US20190169159A1 (en) 2019-06-06
PL2804858T3 (pl) 2020-06-29
AU2013209516A1 (en) 2014-08-28
BR112014017751B1 (pt) 2021-12-07
EP2804858B1 (en) 2019-12-25
CN104136427A (zh) 2014-11-05
EP2804858A4 (en) 2015-07-29
BR112014017751A8 (pt) 2021-03-09
KR20140116939A (ko) 2014-10-06
CA2861339A1 (en) 2013-07-25
CN104136427B (zh) 2017-03-01
AU2017232080A1 (en) 2017-10-12
EA201491385A1 (ru) 2015-02-27
US20150004666A1 (en) 2015-01-01
US20200247779A1 (en) 2020-08-06
IN2014DN06792A (instruction) 2015-05-22
JP2015504095A (ja) 2015-02-05
AU2017232080B2 (en) 2019-02-14
WO2013109998A1 (en) 2013-07-25
EA026209B1 (ru) 2017-03-31
DK2804858T3 (da) 2020-03-16
JP6189865B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
US11247981B2 (en) Metalloenzyme inhibitor compounds
CA2837400C (en) 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
CA2858681C (en) Metalloenzyme inhibitor compounds
CA2915054A1 (en) Metalloenzyme inhibitor compounds
HK1202872B (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180109